Expression of NMDA receptor and microRNA-219 in rats submitted to cerebral ischemia associated with alcoholism

Silva, Cristiane Iozzi; Novais, Paulo Cézar; Rodrigues, Alisson Mendes; Carvalho, C.; Colli, Benedicto Oscar; Carlotti, Carlos Gilberto; Tirapelli, Luís Fernando

doi:10.1590/0004-282x20160188

Cited by 3 publications

(1 citation statement)

References 23 publications

(21 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With its two subtypes, ischemic and hemorrhagic, stroke is among the leading causes of morbidity and mortality. Ischemic cerebral injury accounts for 87% of all stroke cases ( Silva et al, 2017 ; Wu and Tymianski, 2018 ). To date, the recanalization of the occluded vessels with tissue plasminogen activator is the widely used therapeutic option.…”

Section: Introductionmentioning

confidence: 99%

Effect of Mucuna pruriens on brain NMDA receptor and tau protein gene expression in cerebral ischemic rats

Parvatikar

Patil²,

Reddy³

et al. 2023

Front. Physiol.

View full text Add to dashboard Cite

Present study aimed to assess effect of pre-treatment with Mucuna pruriens seed extract and its bioactive molecule(s) on NMDAR and Tau protein gene expression in cerebral ischemic rodent model. Methanol extract of M. pruriens seeds was characterized by HPLC, and β-sitosterol was isolated by flash chromatography. In vivo studies to observe the effect of pre-treatment (28 days) with methanol extract of M. pruriens seed and β-sitosterol on the unilateral cerebral ischemic rat model. Cerebral ischemia induced by left common carotid artery occlusion (LCCAO) for 75 min (on day 29) followed by reperfusion for 12 h. Rats (n = 48) divided into four groups. GroupI (control,Untreated + LCCAO)-No pre-treatment + cerebral ischemia; GroupII(β-sitosterol + Sham)-pre-treatment with β-sitosterol, 10 mg/kg/day + sham-operated; GroupIII(β-sitosterol + LCCAO)-pre-treatment with β-sitosterol, 10 mg/kg/day + cerebral ischemia; GroupIV(methanol extract + LCCAO)-pre-treatment with methanol extract of M. pruriens seeds, 50 mg/kg/day + cerebral ischemia. Neurological deficit score was assessed just before sacrifice. Experimental animals were sacrificed after 12 h reperfusion. Brain histopathology was performed. Gene expression of NMDAR and Tau protein of left cerebral hemisphere (occluded side) was performed by RT-PCR. Results revealed that the neurological deficit score was lower in groups III and IV compared to group I. NMDAR and tau protein mRNA expression in left cerebral hemisphere were upregulated in Group I, downregulated in groups III and IV. Histopathology of left cerebral hemisphere (occluded side) in Group I showed features of ischemic brain damage. Groups III and IV, left cerebral hemisphere showed less ischemic damage compared GroupI. Right cerebral hemisphere showed no areas of ischemia-induced brain changes. Pre-treatment with β-sitosterol and methanol extract of M. pruriens seeds may reduce ischemic brain injury following unilateral common carotid artery occlusion in rats.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of Mucuna pruriens on brain NMDA receptor and tau protein gene expression in cerebral ischemic rats

Parvatikar

Patil²,

Reddy³

et al. 2023

Front. Physiol.

View full text Add to dashboard Cite

show abstract

MicroRNA in glutamate receptor-dependent neurological diseases

et al. 2017

View full text Add to dashboard Cite

Glutamate-mediated excitotoxicity is the major neuropathological process contributing to numerous neurological diseases. Recently, emerging evidence indicates that microRNAs (miRNAs) play essential roles in the pathophysiology of a wide range of neurological diseases. Notably, there have been significant developments in understanding the biogenesis of miRNAs, their regulatory mechanisms, and their potential as effective biomarkers and therapies. In the present review, we summarize the recent literature that highlights the versatile roles played by miRNAs in glutamate receptor (GluR)-dependent neurological diseases. Based on the reported studies to date, modulation of miRNAs could emerge as a promising therapeutic target for a variety of neurological diseases that were discussed in this review.

show abstract

Emerging Impact of Non-coding RNAs in the Pathology of Stroke

Ghafouri‐Fard

Shirvani-Farsani

Hussen

et al. 2021

Front. Aging Neurosci.

View full text Add to dashboard Cite

Ischemic stroke (IS) is an acute cerebral vascular event with high mortality and morbidity. Though the precise pathophysiologic routes leading to this condition are not entirely clarified, growing evidence from animal and human experiments has exhibited the impact of non-coding RNAs in the pathogenesis of IS. Various lncRNAs namely MALAT1, linc-SLC22A2, linc-OBP2B-1, linc_luo_1172, linc-DHFRL1-4, SNHG15, linc-FAM98A-3, H19, MEG3, ANRIL, MIAT, and GAS5 are possibly involved in the pathogenesis of IS. Meanwhile, lots of miRNAs contribute in this process. Differential expression of lncRNAs and miRNAs in the sera of IS patients versus unaffected individuals has endowed these transcripts the aptitude to distinguish at risk patients. Despite conduction of comprehensive assays for evaluation of the influence of lncRNAs/miRNAs in the pathogenesis of IS, therapeutic impacts of these transcripts in IS have not been clarified. In the present paper, we review the impact of lncRNAs/miRNAs in the pathobiology of IS through assessment of evidence provided by human and animal studies.

show abstract

Expression of NMDA receptor and microRNA-219 in rats submitted to cerebral ischemia associated with alcoholism

Cited by 3 publications

References 23 publications

Effect of Mucuna pruriens on brain NMDA receptor and tau protein gene expression in cerebral ischemic rats

Effect of Mucuna pruriens on brain NMDA receptor and tau protein gene expression in cerebral ischemic rats

MicroRNA in glutamate receptor-dependent neurological diseases

Emerging Impact of Non-coding RNAs in the Pathology of Stroke

Contact Info

Product

Resources

About